RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-4482
Malaria parasiteP. berghei
Genotype
TaggedGene model (rodent): PBANKA_1401000; Gene model (P.falciparum): PF3D7_1302500; Gene product: conserved Plasmodium protein, unknown function (PbmaLS_05)
Name tag: EGFP
Phenotype Asexual bloodstage; Liver stage;
Last modified: 3 September 2018, 14:59
  *RMgm-4482
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene tagging
Reference (PubMed-PMID number) Reference 1 (PMID number) : 30154793
Reference 2 (PMID number) : 29515528
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherFernandes P, Mueller AK
Name Group/DepartmentCentre for Infectious Diseases, Parasitology Unit
Name InstituteUniversity Hospital Heidelberg
CityHeidelberg
CountryGermany
Name of the mutant parasite
RMgm numberRMgm-4482
Principal namePbmaLS_05 CT EG FP
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageThrough live imaging of PbmaLS_05 EGFP parasites, we observed expression of the full-length PbmaLS_05 in rings, blood-stage- and liver-stage schizonts. The localization was branched in intra-hepatic parasites during the cytomere stage of development and distinctly more punctuate in blood-stage schizonts, similar to what has previously been observed for parasite mitochondria and apicoplast. Co-staining of PbmaLS_05 EGFP liver stage schizonts, merosomes and blood-stage schizonts with a mitochondrial marker, showed partial co-localization of the PbmaLS_05 protein with the mitochondria.
However, treatment of PbmaLS_05 EGFP liver stages with azithromycin, a drug that inhibits biogenesis of the apicoplast abolished the branched structure observed for PbmaLS_05, even though the mitochondrial structure was retained, suggesting that PbmaLS_05 localizes to the parasite apicoplast. To confirm that PbmaLS_05 localized to the apicoplast of blood-stage parasites, we co-stained PbmaLS_05 EGFP blood-stage schizonts with antibodies against GFP and ACP, an apicoplast-specific protein. Co-localization of both antibodies as observed by the yellow signal in PbmaLS_05 EGFP but not PbANKA WT schizonts confirmed that PbmaLS_05 indeed localizes to the apicoplast of blood-stage schizonts.
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageThrough live imaging of PbmaLS_05 EGFP parasites, we observed expression of the full-length PbmaLS_05 in rings, blood-stage- and liver-stage schizonts. The localization was branched in intra-hepatic parasites during the cytomere stage of development and distinctly more punctuate in blood-stage schizonts, similar to what has previously been observed for parasite mitochondria and apicoplast. Co-staining of PbmaLS_05 EGFP liver stage schizonts, merosomes and blood-stage schizonts with a mitochondrial marker, showed partial co-localization of the PbmaLS_05 protein with the mitochondria.
However, treatment of PbmaLS_05 EGFP liver stages with azithromycin, a drug that inhibits biogenesis of the apicoplast abolished the branched structure observed for PbmaLS_05, even though the mitochondrial structure was retained, suggesting that PbmaLS_05 localizes to the parasite apicoplast. To confirm that PbmaLS_05 localized to the apicoplast of blood-stage parasites, we co-stained PbmaLS_05 EGFP blood-stage schizonts with antibodies against GFP and ACP, an apicoplast-specific protein. Co-localization of both antibodies as observed by the yellow signal in PbmaLS_05 EGFP but not PbANKA WT schizonts confirmed that PbmaLS_05 indeed localizes to the apicoplast of blood-stage schizonts.
Additional remarks phenotype

Mutant/mutation
The mutant expresses a C-terminal GFP-tagged version of PbmaLS_05.

Protein (function)
PbmaLS_05 has a predicted protein size of 306 kDa that contains two predicted transmembrane domains and one predicted P loop containing nucleoside triphosphate hydrolase domain.
The ortholog of PBANKA_140100 (PbmaLS_05), i.e., PF3D7_1302500, was initially identified as a putative antigen that is differentially expressed in intra-hepatic stages of P. falciparum radiation-attenuated sporozoites in comparison to Pf wild-type.

Phenotype
RT-PCR evidence of expression throughout the complete life cycle (in all stages).
Analyses of blood- and liver-stages expressing the GFP-tagged PbmaLS_05: evidence presented for an apicoplast location (see below).

See also RMgm-4481 for a mutant lacking expression of PbmaLS_05. Parasites lacking PbmaLS_05 showed a decreased ability to infect RBC (and immature reticulocytes), Reduced mortality due to experimental cerebral malaria (ECM). Evidence is presented for normal liver stage development.

Additional information
Through live imaging of PbmaLS_05 EGFP parasites, we observed expression of the full-length PbmaLS_05 in rings, blood-stage- and liver-stage schizonts. The localization was branched in intra-hepatic parasites during the cytomere stage of development and distinctly more punctuate in blood-stage schizonts, similar to what has previously been observed for parasite mitochondria and apicoplast. Co-staining of PbmaLS_05 EGFP liver stage schizonts, merosomes and blood-stage schizonts with a mitochondrial marker, showed partial co-localization of the PbmaLS_05 protein with the mitochondria.
However, treatment of PbmaLS_05 EGFP liver stages with azithromycin, a drug that inhibits biogenesis of the apicoplast abolished the branched structure observed for PbmaLS_05, even though the mitochondrial structure was retained, suggesting that PbmaLS_05 localizes to the parasite apicoplast. To confirm that PbmaLS_05 localized to the apicoplast of blood-stage parasites, we co-stained PbmaLS_05 EGFP blood-stage schizonts with antibodies against GFP and ACP, an apicoplast-specific protein. Co-localization of both antibodies as observed by the yellow signal in PbmaLS_05 EGFP but not PbANKA WT schizonts confirmed that PbmaLS_05 indeed localizes to the apicoplast of blood-stage schizonts.

Other mutants 
See also RMgm-4481 for a mutant lacking expression of PbmaLS_05.


  Tagged: Mutant parasite with a tagged gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1401000
Gene Model P. falciparum ortholog PF3D7_1302500
Gene productconserved Plasmodium protein, unknown function
Gene product: Alternative namePbmaLS_05
Details of the genetic modification
Name of the tagEGFP
Details of taggingC-terminal
Additional remarks: tagging
Commercial source of tag-antibodies
Type of plasmid/construct(Linear) PCR construct double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitetgdhfr
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe construct was designed to introduce an EGFP tag at the C terminal end of PbmaLS_05, using the double homologous crossover strategy. A 500 bp fragment corresponding to the 3′ end of the PbmaLS_05 open reading frame (ORF) without the stop codon and a 523 bp fragment from the 3′ UTR region were amplified from P. berghei ANKA genomic DNA. The PCR fragment was then cloned into a b3D + EGFP vector upstream of the EGFP.
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6